{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T18:24:10Z","timestamp":1772389450381,"version":"3.50.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s138270","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T22:12:44Z","timestamp":1501798364000},"page":"2287-2291","source":"Crossref","is-referenced-by-count":17,"title":["Safety of switching from brand-name to generic levetiracetam in patients with epilepsy"],"prefix":"10.2147","volume":"Volume 11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0102-5934","authenticated-orcid":false,"given":"Magdalena","family":"Bosak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"S\u0142owik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Turaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,8]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=37771","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=37771","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T22:12:45Z","timestamp":1501798365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/safety-of-switching-from-brand-name-to-generic-levetiracetam-in-patien-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s138270","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}